Comparative activity of ertapenem and piperacillin–tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli

References

1. Chapin-Robertson K., Edberg S. 1991; Measurement of antibiotics in human body fluids: techniques and significance. In Antibiotics in Laboratory Medicine , 3rd edn. p 295–366 Edited by Lorian V. Baltimore, MD: Williams & Wilkins;
   [Google Scholar]
2. Dela Pena A. S., Asperger W., Kockerling F., Raz R., Kafka R., Warren B., Shivaprakash M., Vrijens F., Giezek H. other authors 2006; Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 10:567–574 [CrossRef]
   [Google Scholar]
3. Freireich E. J., Gehan E. A., Rall D. P., Schmidt L. H., Skipper H. E. 1966; Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50:219–244
   [Google Scholar]
4. Goldstein E. J. C., Snydman D. R. 2004; Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 53:Suppl 2ii29–ii36
   [Google Scholar]
5. Goldstein E. J., Citron D. M., Cherubin C. E. 1991; Comparison of the inoculum effect of cefoxitin and other cephalosporins and of β -lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group. Antimicrob Agents Chemother 35:1868–1874 [CrossRef]
   [Google Scholar]
6. König C., Simmen H. P., Blaser J. 1998; Bacterial concentrations in pus and infected peritoneal fluid - implications for bactericidal activity of antibiotics. J Antimicrob Chemother 42:227–232 [CrossRef]
   [Google Scholar]
7. Li C., Kuti J. L., Nightingale C. H., Mansfield D. L., Dana A., Nicolau D. P. 2005; Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56:388–395 [CrossRef]
   [Google Scholar]
8. Majumdar A. K., Musson D. G., Birk K. L., Kitchen C. J., Holland S., McCrea J., Mistry G., Hesney M., Xi L. other authors 2002; Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 46:3506–3511 [CrossRef]
   [Google Scholar]
9. NCCLS 2003; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically , approved standard. , 6th edn.M7–A6 Wayne, PA: National Committee for Clinical Laboratory Standards;
10. NCCLS 2004; Methods for Antimicrobial Susceptibility Testing for Anaerobic Bacteria , approved standard. , 6th edn.M11–A6 Wayne, PA: National Committee for Clinical Laboratory Standards;
11. Nix D. E., Majumdar A. K., DiNubile M. J. 2004; Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 53:Suppl 2ii23–ii28
    [Google Scholar]
12. Santos K. V., Diniz C. G., Coutinho S. C., Apolônio A. C. M., Sousa-Gaia L. G., Nicoli J. R., Farias L. M., Carvalho M. A. R. 2007; In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures. J Med Microbiol 56:798–802 [CrossRef]
    [Google Scholar]
13. Solomkin J. S., Yellin A. E., Rotstein O. D., Christou N. V., Dellinger E. P., Tellado J. M., Malafaia O., Fernandez A., Choe K. A. other authors 2003; Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 237:235–245
    [Google Scholar]
14. Stearne L. E., van Boxtel D., Lemmens N., Goessens W. H., Mouton J. W., Gyssens I. C. 2004; Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses. Antimicrob Agents Chemother 48:1688–1698 [CrossRef]
    [Google Scholar]
15. Wexler H. M. 2004; In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 53 (Suppl. S2):ii11–ii21
    [Google Scholar]